Our Mission
Flow Pharma engineers and manufactures state-of-the-art biomedicines.
Our unique patented delivery systems and biotechnology are ideally suited for curative intervention in COVID-19, Ebola, and treatment-resistant cancers.
Our Biomedicines
FLOVID-20
COVID-19
A prophylactic needle-free nebulizer treatment to prevent COVID-19 in both virus-exposed and healthy patient populations. A unique targeted T-Cell immunotherapy biomedicine designed to help cure and prevent COVID-19.
FlowVax Ebola
Ebola
By relying on T-cells rather than antibodies, FlowVax Ebola provides long lasting protection through enhanced immune targeting and surveillance of the hidden Ebola virus nucleocapsid protein. FLOVID-20 targets the SARS-CoV-2 virus in the same way.
FlowVax Marburg
Marburg
Marburg is an Ebola-like virus suitable for weaponization by hostile forces. Working directly with the United States Dept. of Defense, we are developing FlowVax Marburg, a prophylactic nebulized biomedicine to protect at-risk military forces and civilians.
FlowVax BreastCA
Cancer
A revolutionary approach to breast cancer that utilizes T-cell biomedicines to provide highly efficacious therapy.
Our Medicine
All COVID-19 patients
deserve meaningful treatment.
Efficacy, Safety, and Convenience are everything. We believe FLOVID-20 can provide it.
Under Development, FDA Approval Required
-
Efficacy
reduced hospitalizations and deaths
-
Safety
using components currently used in FDA approved medications with no observed adverse events in our pre-clinical studies
-
Convenience
inhaled, office-administered, inexpensive, hospital-free